Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that its scientists are presenting research data at two scientific conferences. These oral presentations highlight Trevena's research demonstrating that ligand bias at the angiotensin II type I receptor (AT1R) translates into differentiable and beneficial cardiovascular pharmacology in vivo. The first presentation took place at the Gordon Research Conference: Phosphorylation & G-Protein Mediated Signaling Networks held June 6-11, 2010 at the University of New England in Biddeford, Maine, where Jonathan Violin, Ph.D., Trevena's Head of Biology, presented on June 9 at 8:10 p.m. ET. The second presentation will be given at the 9th Annual World Pharmaceutical Congress being held June 15-17, 2010 at the Sheraton Philadelphia City Center in Philadelphia, Pennsylvania, where Scott DeWire, Ph.D., Senior Research Scientist at Trevena, will present on June 17 at 9:30 a.m. ET.
Trevena recently announced the initiation of a Phase 1 clinical trial of TRV120027, the first biased ligand to be discovered and tested in humans. TRV120027 is a titratable i.v. agent designed for the treatment of acute decompensated heart failure. While blocking angiotensin-mediated G-protein signaling at the AT1R receptor, TRV120027 simultaneously stimulates AT1R-specific β-arrestin signaling. In preclinical studies, this biased ligand has demonstrated a unique range of biological effects that are highly advantageous to patients with acute heart failure. The Phase 1 study of TRV120027 is a single-dose, dose escalation, crossover study in 2 cohorts of healthy subjects. The aims of the study are to assess the safety, tolerability and pharmacokinetics of TRV120027 and the results will inform dose selection and dosing regimens for subsequent studies of TRV120027 in patients with heart failure.
Research shows brain synchronization between humans and dogs